Deadline Passes for Pfizer to Submit Results of Post-Vaccination Heart Inflammation Study to US Regulators

Deadline Passes for Pfizer to Submit Results of Post-Vaccination Heart Inflammation Study to US Regulators
A man is given a COVID-19 vaccine in Chelsea, Mass., on Feb. 16, 2021. Joseph Prezioso/AFP via Getty Images
Zachary Stieber
By Zachary Stieber, Senior Reporter
Updated:

The deadline has passed for Pfizer to submit the results of a study exploring the frequency of heart inflammation following receipt of the company’s COVID-19 vaccine.

Pfizer was required by the U.S. and Food and Drug Administration (FDA) to conduct multiple studies on its vaccine after the FDA approved the shot in August 2021 because regulators determined that without the studies, there would not be sufficient data to assess the “known serious risks of myocarditis and pericarditis,” or heart inflammation and a related condition.
Zachary Stieber
Zachary Stieber
Senior Reporter
Zachary Stieber is a senior reporter for The Epoch Times based in Maryland. He covers U.S. and world news. Contact Zachary at [email protected]
twitter
truth
Related Topics